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The conserved oligomeric Golgi (COG) complex is a hetero-octameric complex essential for normal glycosy-
lation and intra-Golgi transport. An increasing number of congenital disorder of glycosylation type II (CDG-II)
mutations are found in COG subunits indicating its importance in glycosylation. We report a new CDG-II
patient harbouring a p.R729W missense mutation in COG4 combined with a submicroscopical deletion.
The resulting downregulation of COG4 expression additionally affects expression or stability of other lobe
A subunits. Despite this, full complex formation was maintained albeit to a lower extent as shown by glycerol
gradient centrifugation. Moreover, our data indicate that subunits are present in a cytosolic pool and full com-
plex formation assists tethering preceding membrane fusion. By extending this study to four other known
COG-deﬁcient patients, we now present the ﬁrst comparative analysis on defects in transport, glycosylation
and Golgi ultrastructure in these patients. The observed structural and biochemical abnormalities correlate
with the severity of the mutation, with the COG4 mutant being the mildest. All together our results indicate
that intact COG complexes are required to maintain Golgi dynamics and its associated functions.
According to the current CDG nomenclature, this newly identiﬁed deﬁciency is designated CDG-IIj.
INTRODUCTION
The Golgi apparatus is an important relay station in the
secretory pathway as it plays a pivotal role in targeting proteins
and lipids to distinct post-Golgi compartments (1). During
transit through the Golgi apparatus, most of the newly syn-
thesized secretory and membrane-bound proteins undergo
major modiﬁcations, mainly involving different types of glyco-
sylation. One of these, N-glycosylation, is a complex series of
reactions, starting in the endoplasmic reticulum (ER) with the
formation of a Glc3Man9GlcNAc2-PP-Dolichol structure,
which is subsequently transferred onto newly synthesized pro-
teins (2). Upon exit from the ER and arrival in the Golgi,
these unprocessed N-glycan chains are trimmed and modiﬁed
to give rise to distinct types of complex N-glycan structures.
Most of the other types of glycosylation, like the formation of
O- and C-glycans, are restricted to either the ER or the Golgi
apparatus. To maintain the directional ﬂow of transport, essen-
tial for these modiﬁcations, the Golgi apparatus is built out of
stacked cisternae, laterally interlinked via fenestrated continu-
ities. The differential distribution of proteins and enzymes
overthesestacksprovidestheGolgicomplexwithacis-to-trans
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required in order to mediate cargo transit as well as to maintain
the cis-to-trans organization. The exact mechanism of this
transit is still not clariﬁed, though it will most likely be a com-
bination of the vesicular transport model, which implicates
ﬁxed cisternae with vesicles transporting cargo forward and
recycling escaped proteins to earlier cisternae or the ER (4–
7) and the cisternal maturation model. In the latter model, the
cisternae mature towards the trans-side while vesicles con-
stantly recycle enzymes back to earlier compartments (8,9).
More recently a two-phase membrane system was proposed in
which small soluble cargo distributes equally across the stack
and membrane proteins prefer certain cisternae only based on,
for instance, the local lipid composition and length of the trans-
membranedomain(10).Irrespectiveofthedifferentmodelsand
itsspeciﬁcityanddirectionality,intra-Golgitransportrequiresa
large number of proteins and protein complexes. These include
COPI-coat proteins and associated small GTPases, like ARF1
mediating budding/ﬁssion, as well as ‘Soluble NSF attachment
protein receptor’ family members that govern vesicle fusion.
The targeting speciﬁcity is often organized through the con-
certed action of GTP-bound Rab proteins with so-called tether-
ing complexes, which are soluble multimeric complexes,
coupling incoming organelles with the fusion site. One
example is the exocyst complex that acts as a tethering
complex at the cell surface of budding yeast and in mammalian
cells. The main tethering complexes in the early secretory
pathway are the ‘Transport Protein Particle’ (TRAPP) I and II
complexes which couple ER-derived vesicles to the ER-Golgi
intermediate compartment and the conserved oligomeric
Golgi (COG) complex which appears to function in intra-Golgi
and/or Golgi-to-ER trafﬁcking.
The COG complex is an octameric hetero-oligomer con-
served from yeast to mammals and presents as a bi-lobed struc-
ture bridged through the COG1–COG8 interaction (11,12).
Deﬁciencies in single subunits lead to impaired functioning of
the COG complexes, concomitant defects in Golgi morphology
(13) and affecting the correct functioning of the cell or entire
organism. For instance, a deﬁciency of COG1 or COG2 in
CHOcelllinesshowedadefectiveretrogradeGolgi-to-ERtrans-
port, a subsequent disturbance of the Golgi morphology and a
destabilization of several proteins, including glycosylation
enzymes, thus causing glycosylation abnormalities. The impor-
tanceofCOGfunctioninintra-Golgitransportanditssecondary
implications on glycosylation are furthermore underscored by
the discovery of mutations in the genes encoding the COG1,
COG7 and COG8 subunits that were linked to congenital dis-
ordersofglycosylation(CDG)(12,14–19).CDGisarare,reces-
sive disorder ﬁrst described in 1980 (20,21). Since then, 22
subtypes have been described, which can be divided into two
different groups: CDG type I and type II. CDG type I (CDG-I)
is caused by defects in enzymes governing the synthesis and
transfer of the oligosaccharide in the ER. On the other hand,
defects leading to CDG-II have been shown to belong to differ-
ent classes: enzymes responsible for the modiﬁcations of the
N-glycan chain in the Golgi apparatus, sugar transporters in
the Golgi membrane and complexes essential for intra-Golgi
andretrogradeGolgi-to-ERtransportsuchastheCOGcomplex.
Here we describe a patient harbouring a heterozygous point
mutation in the COG4 gene combined with a deletion on the
maternal allele. Experiments performed on this patient’s ﬁbro-
blasts yielded similar defects albeit less severe as found in the
cells of the previously described COG-deﬁcient patients.
Moreover, we present an updated overview of the different
COG mutations identiﬁed thus far in which we attempt to cor-
relate for the ﬁrst time the respective clinical phenotypes with
the severity in glycosylation and trafﬁcking defects as well as
with the Golgi integrity using transmission electron
microscopy (TEM). Our analysis underscores the high impor-
tance of an intact COG complex in both intra-Golgi trafﬁcking
and the maintenance of the normal morphology of the Golgi
apparatus. Furthermore, we provide novel insights in the
steady-state localization of both full and partial complexes
with implications on the action mechanism of the complex.
With this study, the number of patients harbouring mutations
in individual COG genes rises to ten, which is about one-third
of the total number of CDG-II cases in which a mutation has
been identiﬁed making COG mutations one of the most fre-
quent causes of CDG-II. Furthermore, given the insights that
the different individual studies have generated on COG
complex formation and functioning, we are now at a point
where a comparison of all mutant subunits along different cri-
teria reveals more speciﬁc or even as yet unknown functions of
not only the full complex, but also of different subunits and
subcomplexes.
RESULTS
Genetic and molecular analysis of COG4
The identiﬁcation of several CDG type II patients harbouring
mutations in individual subunits of the octameric COG
complex fostered a strong interest in the functional role this
Golgi tethering complex plays in the glycosylation process.
By direct sequencing of the COG genes in a cohort of
unsolved CDG-II patients, we identiﬁed a novel patient carry-
ing a seemingly homozygous C.T point mutation at position
2185 in the genomic DNA encoding the COG4 gene (Fig. 1A).
The mutation was not found after sequencing of over 100
alleles of a randomly chosen European control population.
At the protein level, this mutation converts a highly conserved
arginine 729 (Fig. 1B) into a tryptophan residue (p.R729W).
Sequencing of the parental DNA conﬁrmed the father as
being heterozygous for this mutation, whereas the mother
only presented the normal sequence (Fig. 1A). A de novo
mutation on the maternal allele was excluded by the identiﬁ-
cation of two single nucleotide polymorphisms (SNPs), in
exon 5 and exon 18, which also showed an abnormal inheri-
tance pattern, i.e. the patient having no obvious maternal con-
tribution for the COG4 allele (data not shown). A uniparental
paternal isodisomy of (a part of) chromosome 16 could also be
excluded (data not shown). Fluorescence in situ hybridization
using fosmid clones demonstrated a deletion of clone
G25P85580E2, pointing to a submicroscopical deletion on
the maternal allele (Fig. 1A). On the basis of the results of
other fosmids, we inferred that the ﬁrst two exons of the
COG4 gene are present, whereas the 30 breakpoint should be
located in a 5 kb region between intron 2 and the ﬁfth exon.
The proximal breakpoint has not been identiﬁed but, based
on SNP mapping, we delineated a 47 kb region containing
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ental inheritance pattern was rs3852695, located 97 kb
upstream of the COG4 start codon, whereas rs7192865 was
the ﬁrst hemizygous SNP, located 50 kb upstream of COG4
(Fig. 1A). The only other gene (largely) included in the del-
etion is the FUK gene, just upstream of the COG4 gene.
This gene encodes the L-fucose kinase, necessary for the reu-
tilization of fucose after the degradation of oligosaccharides
(22). Since no decreased fucosylation was observed in the
N-glycans of our patient, we conclude that the (partial) monos-
omy of this gene is not pathogenic. In our opinion, the COG4
deletion and point mutation are the sole responsible for the
identiﬁed clinical and cellular abnormalities. This mutation
deﬁnes a new subtype of CDG-II, which we named the
COG4 defect (COG4/CDG) or CDG-IIj.
The patient described here is the ﬁrst child of healthy, unre-
lated Portuguese parents. Until the fourth month the boy had a
normal development, but after a vaccination the child started
fever and progressive irritability. He was hospitalized due to
complex seizures, which were eventually suppressed by
phenobarbital. Some dysmorphic features were noted, like a
peculiar face (down sloping frontal area and thick hair) com-
bined with axial hyponia, slight peripheral hypertonia and
hyperreﬂexia. Blood tests revealed increased serum transamin-
ases, alkaline phosphatases and LDH cholesterol levels, while
the platelet counts were down. Because CDG was suspected,
isoelectric focusing of serum transferrin was performed and
showed a type 2 pattern (Supplementary Material, Fig. S1).
Brain MRI, ophtamological and cardiological investigations
were normal, as well as serum immunoglobulins and hor-
mones, but a decrease of coagulation factors was noted.
Since the age of 12 months he was regularly admitted to the
hospital due to recurrent respiratory infections. At the age of
3 years the child presented with microcephaly, bilateral cer-
ebral atrophy of the frontotemporal regions, a mild degree of
ataxia, brisk, uncoordinated movements, absence of speech
and moderate psychomotor delay.
COG subcomplexes reside in the cytosol
The combination of both the mutant COG4 and the deleted
allele has a dramatic effect on COG4 protein levels that
drop to 20% in the patient’s ﬁbroblasts compared with
control (Fig. 1C). Interestingly, the low COG4 levels also
affected the other subunits of lobe A by 50% for COG3,
40% for COG2 and 25% for COG1. In lobe B only a 40%
decrease was observed for COG5, whereas all others remained
indistinguishable from the control. We can thus conclude that
the COG4 mutation mainly renders lobe A subunits instable
without affecting dramatically (except for COG5) lobe B sub-
units. Western blot analysis for COG4 on extracts derived
from maternal and paternal ﬁbroblasts displayed normal
Figure 1. Genetic and molecular characterization of the described COG4 patient. (A) Sequencing revealed a heterozygous C.T missense mutation in the patient
and the absence of this mutation in the mother. The ﬂuorescence in situ hybridization (FISH) image shows the deletion of fosmid G24P85580E2 (red) on the
maternal allele, whereas the control subtelomeric 16q fosmid (green) shows a normal signal. A schematic representation of the mutations present in the patient is
given, the green and red asterisk on the maternal allele indicate, respectively, the last heterozygous SNP and the ﬁrst hemizygous SNP in the patient, the black
asterisk on the paternal allele indicates the position of the missense mutation, green regions indicate genes (. ....: sense/, ...,: antisense/bars indicate the
location of each gene) and intergenic regions that are present in the patient, the white and grey regions on the maternal allele indicate, respectively, the known
deleted region and the region containing the proximal breakpoint. (B) Alignment of the COG4 sequence of different species shows an absolute conservation of
this residue. (C) Lysates of a control, the COG4 patient and both parents were loaded on SDS–PAGE gel to analyze the COG4 levels. Quantiﬁcations represent
the mean values of three independent loadings of independent samples. Error bars represent the SEM, a Student t-test resulted in a highly signiﬁcant P-value
( 0.001—indicated as     ) when comparing control and patient. (D) Western blot of control and patient for all COG subunits. Quantiﬁcations represent the
mean values of three independent loadings of independent samples. Error bars represent the SEM, a Student t-test was used to obtain the P-values indicated in the
graph as  /   /    , representing, respectively, P   0.1/P   0.01/P   0.001.
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(Fig. 1D). Hence, the second, normal allele likely compensates
for the deletion, explaining the absence of any phenotypical
abnormalities in the mother. With respect to the father, the
COG4 levels are slightly affected, suggesting that the mutant
COG4 is more prone to degradation.
We next explored the effect of decreased mutant COG4
levels on the integrity of the full COG complex. Cytosolic
and membrane extracts of control and COG4 patient ﬁbroblasts
were fractionated by glycerol gradient centrifugation and
analyzed by western blotting. No apparent differences in the
size distribution of the COG complexes were noticed when
compared with control cytosolic and membrane fractions
(Fig. 2A). This demonstrates that, despite the mutant COG4
and lowered levels of several individual COG subunits, com-
plexes can still be formed. This contrasts with the observations
made for the COG8-deﬁcient patient (12). On the other hand,
weobservedcleardifferencesbetweencytosolicandmembrane
extracts with COG complexes distributing in much lighter frac-
tions of the cytosolic gradients and in a more restricted manner
(fractions 2–6). In comparison, the 669 kDa marker thyroglo-
bulin was recovered mainly in fraction 6. In the case of mem-
brane extracts, COG subunits were more broadly distributed
and found in higher fractions as well. Moreover, when compar-
ingtheabsoluteamountsofcytosolicandmembrane-associated
COGsubunits,mostisrecoveredinthecytosol(Fig.2B).Taken
together, these results suggest that the full complex, with an
estimated weight of 800 kDa, is mainly present on the mem-
brane. The broad distribution of the COG proteins in the mem-
brane gradients indicates that both the full complex and
subcomplexes coexist in the membrane. The cytosol contains
the major pool of COG proteins, but mainly in the form of sub-
complexes,probablycorrespondingtolobeAandB.Inthelight
of this, it is tempting to suggest that subcomplexes present on
the vesicle and target membrane recombine to full COG com-
plexes upon tethering of the incoming vesicle with the Golgi
membrane. Alternatively, we cannot exclude that full com-
plexes are assembled in the cytosol and then immediately
recruited to the membrane, initiating vesicle tethering (see Dis-
cussion). These results are in agreement with previous data on
the COG8-deﬁcient patient where Foulquier et al. (12)
showed that the cytosolic COG proteins in the patient were
Figure 2. The COG4 mutation does not abrogate normal assembly of the full complex. (A) Glycerol gradient centrifugation was performed on cytosolic and
membrane fractions of a control (C) and the COG4 patient (P4), all 12 fractions obtained were loaded onto SDS–PAGE gels and the distribution of COG3,
-4, -7 and -8 was analyzed using western blot, asterisks indicate the migration of the 669 kDa marker thyroglobulin. Exposure times differ between cytosolic
and membrane fractions, due to the mainly cytosolic localization of the complex. (B) Cytosol and membrane fractions were obtained from the cells of a control
and the COG4 patient. Quantiﬁcations after western blot shows that there is no difference between the COG4 distribution in control and patient’s cells. (C)
Glycerol gradient centrifugation was performed on membrane fractions of a control (C) and the COG8 patient (P8), all 12 fractions obtained were loaded
onto SDS–PAGE gels and the distribution of the COG1, -3 and -8 proteins was analyzed using western blot, asterisks indicate the migration of the 669 kDa
marker thyroglobulin. Exposure times differ between cytosolic and membrane fractions, due to the mainly cytosolic localization of the complex.
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When extending this analysis to the membrane fractions of
the COG8 patient’s ﬁbroblasts in this study, we also noticed a
more restricted distribution towards lighter fractions in accord-
ance with the lack of full COG complex assembly on the mem-
brane in COG8 patient ﬁbroblasts (Fig. 2C). Upon comparison
of the percentage of the COG3, -4, -7 and -8 proteins in the
different fractions, the complexes in the cytosol appear deﬁ-
nitely smaller, whereby only the COG8 patient showed a
defect in full complex formation (Supplementary Material,
Fig. S2). These data seem to be in disagreement with the
reports on yeast and CHO cells, reporting the presence of the
majority of the COG proteins in the full complex (13,23–27).
However, we feel caution is needed when extrapolating exper-
iments from different organisms to primary human ﬁbroblasts,
since differences in the mechanism of the formation of the full
complex cannot be excluded.
At the endogenous level, all COG subunits show a preferen-
tial localization to the Golgi region as demonstrated by the
colocalization with GM130, a cis-Golgi marker. Similar obser-
vations were made in the COG4 patient’s ﬁbroblasts where all
COG proteins localized to the Golgi (Supplementary Material,
Fig. S3), in spite of the very low levels of mutant COG4 (and
other subunits) in these cells. The absence of a signiﬁcantly
different localization could be due to the large cytosolic
pool from which subcomplexes can be recruited. These and
previous ﬁndings suggest that the mutation in COG4 generates
a more subtle effect in the COG complex function, for instance
by affecting recruitment of other regulatory components in
membrane tethering.
The degree of Golgi dysfunction grossly correlates
with the clinical phenotype
Next we compared this patient with three patients harbouring
mutations in COG1, COG7 or COG8 (12,15,17) on multiple
parameters. With respect to the clinical phenotypes (Table 1
and Supplementary Material, Table S1), it is evident that the
COG7 patient is most affected. Also the clinical phenotype
of the COG8 patient is quite severe, whereas the COG4 and
mainly the COG1 patients present with milder problems.
The question now rises whether this correlates with the
defects observed at the cellular level.
The initial classiﬁcation of patients with mutations in COG
subunits as CDG-II already identiﬁes them with defects in the
maturation of the N- (and O-) glycan chains and implicates a
crucial role of the COG complex in the normal glycosylation
reaction as observed also in COG subunit deﬁcient cells
(13,28). Indeed, a comparative mass-spectrometric analysis
of N-glycans on serum samples of four COG-deﬁcient
CDG-II patients reveals multiple abnormal oligosaccharide
structures and changes in the relative amounts of individual
oligosaccharides. A common observation between all COG
patients is the decrease in or lack of sialylation (Fig. 3A–
B). With respect to this, the COG1 and COG4 patients are
most, respectively least, severely affected. When comparing
the galactosylation of the N-glycans, both COG1 and COG7
patients were most affected with agalactosylated glycan struc-
tures in, respectively, 11 and 40% of the glycans. This result
was striking since in the described CDG-IId patient this
defect is not observed, despite a proven 95% reduction in
the b-1,4-galactosyltransferase-1 (b-1,4-GalT1) enzyme
activity (29). One explanation could be that the altered recy-
cling of the b-1,4-GalT1 enzyme, due to COG deﬁciencies,
has a more severe effect on the formation of the correct
glycan structure than a reduced b-1,4-GalT1 expression.
Furthermore, only in these two patients, Man5GlcNAc2 struc-
tures were abundantly detected. The absence of a third
N-acetylglucosamine (GlcNAc) monosaccharide is most
likely due to a decreased N-acetylglucosaminyl transferase 1
(GlcNAcT1) activity rather than a destabilization of ManII
since mannose (Man) N86 and N88 can only be cleaved after
a GlcNAc residue is added onto the free mannose N82b y
GlcNAcT1. Both the GlcNAcT1 and ManII enzymes reside
Table 1. Comparison of the different patients for all investigated defects
COG1 COG4 COG7 COG8
Clinical phenotype Failure to thrive Mild psychomotor retardation Lethal Encephalopathy
Hypotonia Growth retardation Neurological and
psychomotor regression
Mild psychomotor
retardation
Mild dysmorphia Dysmorphia Hypotonia
Growth retardation Epilepsia Hyperthermia Mild mental retardation
Mutation(s) c.2659-2660insC
p.P888fsX900
c.2185C.T p.R729W
submicroscopical deletion
16q22
c.IVS1þ4A.C altered splicing
leading to frame shift and stop
codon
c.1611C.G p.Y537X
Origin Portuguese Portuguese Moroccan Spanish
Publication Foulquier et al. (15) This publication Wopereis et al. (17) Foulquier et al. (12)
BFA defect (% cells with
Golgi remnants)
74.6+2.5 22+3.5 88.8+2.33 34.4+7.9
Glycosylation defects Sialylation Sialylation (Galactosylation) Sialylation Sialylation
Galactosylation Galactosylation Galactosylation
Demannosylation Demannosylation
Golgi morphology Typical Golgi stacks (as
in WT)
Typical Golgi stacks (as in WT) Many undulated Golgi stacks with
many swollen cisternae
Some undulated Golgi
stacks
Some undulated Golgi
stacks
Some undulated Golgi stacks, less
rigid
Less rigid Golgi stacks Fragmented Golgi
Few fragmented/
disrupted Golgi.
Few fragmented/disrupted Golgi Many tubular and
vesicular proﬁles
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one another, in order to ensure their sequential activity. Our
observation is in line with earlier data on the depletion of
either lobe A or lobe B of the COG complex, which severely
affects localization of medial-Golgi enzymes such as
GlcNAcT1 and ManII (30) and which in turn suggests a
Golgi disorganization.
Even though the glycosylation defect allowed us to classify
these patients as CDG-II, it is likely not the primary defect.
The aberrant glycosylation may result from the abnormal
transport or distribution of glycosylation enzymes and poss-
ibly also nucleotide-sugar transporters. To test the integrity
of the retrograde Golgi-to-ER trafﬁcking, we treated patient
cells for 6 min with Brefeldin A (BFA), a fungal metabolite
that rapidly redistributes Golgi enzymes to the ER (31–33),
and counted the number of cells which still showed Golgi rem-
nants (Fig. 4B). While in the control virtually, no cells could
be detected with Golgi remnants, as measured by ManII
immunoreactivity (Fig. 4A), its BFA-induced redistribution
was signiﬁcantly delayed in patient cells, most dramatically
in COG7 and COG1 mutant cells (respectively, 90% (SEM:
+2%) and 75% (+2%) of cells with Golgi remnants). A sig-
niﬁcant but less severe retrograde transport delay was
observed in the COG4 and COG8 ﬁbroblasts. The difference
between COG4 and COG8 cells persisted in shorter BFA treat-
ments but caught up with longer treatments (data not shown).
On the contrary, no differences were found after 90 min of
BFA wash-out, this time point was chosen since shorter incu-
bations resulted in only a partial restoration of the Golgi in
control cells (Fig. 4A) These data indicate no delay in antero-
grade transport and Golgi restoration in the COG-deﬁcient
patient cells.
We next attempted to rescue the BFA-induced retrograde
transport defect in COG4 patient cells by introducing wild-
type COG4 using retroviral transduction. BFA-treatment of
these transduced cells did not result in a normalized retrograde
trafﬁcking (Fig. 5A). Surprisingly, stable transduction of
control cells with COG4 (thereby doubling expression
levels) resulted in a retrograde trafﬁcking defect, reminiscent
of that observed in patient cells. This indicates that COG4
overexpression leads to a dominant-negative effect on trafﬁck-
ing making rescue experiments very difﬁcult. Therefore, we
down-regulated COG4 in HeLa cells to try and mimic the
transport defect observed in the patient’s cells, by transfection
of these cells with a ‘smart pool’ of four different RNAi oligo-
nucleotides. This yielded a reproducible and nearly complete
Figure 3. Presence of abnormal N-glycosylated proteins in the serum of the COG-deﬁcient patients. (A) Mass spectrometry results of serum samples of all known
patients and a control, show a deﬁciency in the N-glycosylation pathway in the Golgi apparatus in all patients. (B) Quantiﬁcation of the results shown in (A), the
control values are the mean of the results obtained from serum samples of three independent controls. All patients have a clear decrease in sialylation of their
N-glycan chains (m/z 2431 and 2605), furthermore the COG1 and -7 patients also show a remarkable galactosylation (m/z 2040) and demannosylation (m/z
1580) deﬁciency.
Human Molecular Genetics, 2009, Vol. 18, No. 17 3249downregulation of COG4 (3.2+3.5% remaining protein)
when compared with untreated or mock-transfected cells
(Fig. 5B). Subsequent BFA treatment showed a signiﬁcant
delay in ManII re-distribution underscoring that the mutations
in the patient result in a trafﬁcking delay and are likely to be
pathogenic (Fig. 5B).
Ultrastructural support for a role for the COG complex
in maintaining Golgi integrity
Since Golgi integrity is maintained dynamically, we predicted
that COG subunit mutations or deﬁciencies may alter Golgi
morphology. Using confocal microscopy, we indeed noticed
dilatation and fragmentation of the Golgi in all patients’
cells (data not shown). However, since confocal microscopy
does not give the resolution needed to observe the speciﬁc
and subtle changes we decided to perform TEM analysis on
all patient cells. The overall Golgi integrity was substantially
to very severely disrupted in all investigated cell lines,
although some distinct observations could be made (Fig. 6
and Supplementary Material, Fig. S4). First, only in COG1
and, albeit to a lesser extent, in COG4 cells few typical
Golgi cisternae could still be discerned. In COG7 and COG8
patient cells on the contrary, virtually no normally organized
stacks were found. In these cells, individual Golgi stacks
had an undulated appearance suggesting a decreased rigidity
maybe caused by a weaker connection to the underlying cytos-
keleton, although this remains to be investigated. Further,
fragmented or vesiculated Golgi membranes were predomi-
nantly observed in the COG8-deﬁcient cells and less frequent
Figure 4. Cells of all known COG patients show trafﬁcking defects. (A) Cells of all patients and four controls were treated with Brefeldin A for 6 or 60 min
followed by wash-out of the drug. Cells were stained for GM130 and ManII, 300 cells were counted per cell line and based on the ManII staining each counted
cell was scored for the presence or absence of Golgi (remnants), the results are averages of three independent experiments per cell line, the error bars represent
the SEM, a Student t-test was used to obtain the P-values indicated in the graph as   /    , representing, respectively, P   0.05/P   0.001. (B) Representative
confocal laser scanning microscopy (CLSM) images of control and patient cells obtained after staining for GM130 (green) and ManII (red). Both 60  and
representative zoomed pictures are shown, scale bars represent 10 mm.
3250 Human Molecular Genetics, 2009, Vol. 18, No. 17in COG4 and COG1 cells. Fragmentation was not clearly
observed in the COG7 cells but instead the Golgi areas pre-
sented with many individual swollen cisternae (asterisk in
Fig. 6). Such swollen cisternae were also frequently seen in
COG8 cells. It should be noticed that at the EM level many
COG7 patient cells appeared necrotic indicating that the
observed ultrastructural defects in the surviving cells are an
underestimation of the true phenotype. Again, a correlation
can be found between the severity of the disease and the cor-
responding ultrastructural defects. Surprisingly, however, and
in spite of having severe structural deﬁcits in Golgi integrity
and transport, patient cells still maintain a signiﬁcant degree
of complex glycosylation.
DISCUSSION
Clinical comparison of different COG-deﬁcient
CDG-II patients
The present study identiﬁes a novel mutation in the COG4
subunit of the COG complex (designated as CDG-IIj), which
further expands the subgroup of CDG-II cases caused by
mutations in the COG complex (12,14–19). Thus far,
mutations have been detected in the COG1, COG7 and
COG8 subunits and range from premature stop codons in the
COG1 and COG8 to splice site mutations in the COG1 and
COG7 subunits. Here, we describe a missense mutation com-
bined with a microdeletion in COG4. The clinical and cellular
phenotypes in these patients differ accordingly from mild to
severe or lethal (Table 1 and Supplementary Material,
Table S1). Herein, the COG4 phenotype is one of the
mildest in this subcategory of CDG-II. Most severe are the
COG7-deﬁcient patients displaying early post-natal lethality.
The overall phenotype of the COG8 patient, presenting with
neurological regression, cerebellar atrophy and hypotonia, is
in between that of the COG7 and COG4 patients. While the
COG1 mutation causes an early stop codon and hence a
large C-terminal truncation, the patient suffers only from
mild psychomotor retardation.
Effects of the p.R729W COG4 mutation on complex
formation and its function
The COG4 patient is compound heterozygous for a R729W
point mutation and a submicroscopical deletion. In heterozy-
gous state, the individual gene defects do not compromise
COG function given the absence of clinical features in both
parents. The combination, however, results in 20% reduced
levels of the mutant COG4 subunit and consequently, the
levels of the corresponding lobe A subunits are also signiﬁ-
cantly reduced, a feature reminiscent of COG mutations
(12,14–19). Unexpectedly, a signiﬁcant drop in COG5, a
lobe B subunit, was observed suggesting interaction of
COG5 with lobe A (subunits). In support, COG5 was demon-
strated in vitro to interact with COG4 (11) as well as with
COG1 (27). Nevertheless, the remaining mutant COG4
protein retains its capacity to integrate in an octameric COG
complex as demonstrated by glycerol gradient centrifugation.
This also implies that the destabilized COG1, which bridges
both lobes through its interaction with COG8, is still present
in sufﬁcient amounts for complex formation (12,24). Our
data therefore suggest the existence of a pool of subunits or
subcomplexes from which full complexes can be assembled
according to the cellular needs. Hence in the COG4 patient
cells, the reduced lobe A levels are apparently sufﬁcient to
maintain a basal level of COG complex formation. Indeed,
the fact that over 90% of the COG proteins are cytosolic
and mostly distributing in the lighter fractions of the gradient
suggests that they are predominantly associated in their lobe A
or B conﬁguration. On the other hand, when analyzing
Figure 5. Effects of COG4 overexpression and downregulation on the retrograde trafﬁcking defect. (A) Patient and control cells were transduced with COG4-
containing viral particles, the resulting overexpression was analyzed on western blot and compared with COG4 levels present in untreated control and patient
cells. After BFA treatment of all four cell lines the percentage of abnormal cells was counted, based on ManII staining, results are averages of three independent
BFA treatments, error bars represent the SEM. (B) HeLa cells were transfected three times independently with a ‘smart pool’ of RNAi oligo’s speciﬁc for the
COG4 sequence (S). The extent of downregulation was assessed using western blot and compared with untreated cells (UT) and cells treated with a non-speciﬁc
oligo (NS). The percentage of abnormal cells, counted after BFA treatment and ManII staining, is represented in the graph as an average of three different exper-
iments. Error bars represent the SEM, a Student t-test was performed resulting in a signiﬁcant P-value of 0.022, when compared with the untreated cells.
Human Molecular Genetics, 2009, Vol. 18, No. 17 3251membrane extracts, most subunits are trailing broadly over
almost the complete gradient suggesting an additional associ-
ation in higher order complexes, likely the full COG complex.
The observation that mutant COG8 membrane extracts (in
which the lobe A and B bridging is disrupted) lack this trailing
indicates that in this case only (partial) subcomplexes are
membrane bound. In the light of these data, it is tempting to
suggest two possible mechanisms in which the COG
complex could tether incoming vesicles. First, lobe A and B
might be recruited to the membrane of either the incoming
vesicle or the target (Golgi cisternal) membrane. When in
close proximity, both lobes can combine to a full complex
thereby tethering the transport vesicle to the cisterna. After
fusion, the full complex dissociates from the membrane and
into subcomplexes (Fig. 7A). This model is in agreement
with the proposed working mechanism of the exocyst
complex at the cell surface. It has been reported that the
Sec3p and Exo70p exocyst subunits localize to the target
membrane, whereas the others are recruited to the vesicle
and full complex formation assists tethering (34). On the
other hand, and in analogy to the TRAPP complex (34), all
eight subunits might assemble in the cytosol and be recruited
to either the vesicular or target membrane and assist tethering
after capture of the vesicle by other proteins, such as p115 for
which an interaction with COG2 has been demonstrated (35)
(Fig.7B). However, giving the striking similarity in the
sequence and structure between subunits of the exocyst and
COG complex (36,37, Richardson et al., manuscript in prep-
aration), the ﬁrst model is favoured here. Whether the recruit-
ment of both lobes, or the full complex occurs directly through
lipid interactions or via yet to be identiﬁed membrane proteins
on the vesicle and/or cisternal membrane remains to be
explored.
The presence of a major cytosolic reserve pool is supported
by immunolocalization studies that showed no signiﬁcant
alterations in the Golgi association of the mutant COG4 or
other COG subunits. Only in more dramatic cases, such as
in the human ﬁbroblasts deﬁcient in COG 1, COG7 or
COG8 (12,14,15) but also after knock-down of COG2,
COG3 or COG5 (28,38), the steady-state localization of
some of the cognate subunits was affected; this is likely due
to the abrogation of inter-subunit interactions caused by e.g.
the truncation or destabilization of the COG1 and/or COG8
proteins.
Cellular implications of single COG subunit deﬁciencies
At the cellular level, all COG mutations display a signiﬁcant
mild to severe delay in BFA-induced redistribution of Golgi
enzymes (as evidenced by mannosidase II) or Golgi matrix
Figure 6. Analysis of the Golgi morphology at the submicroscopical level. Cells of all patients and one control were subjected to electron microscopy. Both the
COG1- and COG4-deﬁcient patient cells still show some stacks with a normal morphology, in contrast to the COG7 and COG8 patients. The most striking
ﬁnding mainly in the COG7 and COG8 patients was the undulated appearance of the stacked cisternae, as indicated by the arrowheads. Furthermore, several
stacks have a fragmented and/or vesiculated appearance, indicated by arrows, a phenotype which is most severe in the COG8 patient. The asterisks indicate
swollen cisternae which were present in a differing degree in all patients. The ‘.‘points to clathrin-coated vesicles, indicating the trans-side of the
Golgi apparatus.
3252 Human Molecular Genetics, 2009, Vol. 18, No. 17proteins (such as GM130) to the ER, ER exit sites or peri-
nuclear vesicular structures (32,39,40). The lack of any
effect in BFA wash-out experiments clearly indicates a retro-
grade transport defect and a putative role for the COG
complex in tethering retrograde transport vesicles to the ante-
cedent cisternae as predicted by the cisternal maturation model
(8,9,41–43). Any defect in retrograde intra-Golgi trafﬁcking
and tethering is likely to affect Golgi morphology due to
imbalanced transport of e.g. cargo. Indeed ultrastructural
analysis revealed abundant Golgi fragmentation, vesiculation
and cisternal vacuolization in all mutant COG ﬁbroblasts
largely correlating with the severity of the mutations and the
observed delays in BFA-induced redistributions. In agreement,
overall Golgi fragmentation, often associated with vacuolated
cisternae, was observed for the ldlB and ldlC mutant CHO
cells, deﬁcient in either COG1 or COG2 (13,44). Downregula-
tion of COG3 resulted in the formation of Golgi mini-stacks
and an extensive accumulation of small vesicles distinct
from COPI-coated vesicles (38), whereas knockdown of
COG5 in CHO cells showed dilated Golgi cisternae (45).
Finally, mutants of the yeast COG4 homologue, Sgf1,
showed an accumulation of membranes, most likely Golgi
transport vesicles (46). These ﬁndings underscore our ﬁndings
that a deﬁciency in a given COG subunit substantially affects
Golgi integrity. On the other hand, we also observed unex-
pected and novel alterations of the Golgi morphology includ-
ing the presence of undulated cisternae (e.g. in COG7 and
COG8 patients’ cells). This points to a destabilization in the
connection of the Golgi cisternae with the underlying cytoske-
leton and suggests, besides a role in retrograde transport, an
additional function of the COG complex (or one or more of
its subunits) in tethering Golgi membranes to microtubules.
Given their Golgi localization, the observed defects in Golgi
transport and morphology, COG subunit mutations are prone
to affect the Golgi glycosylation processes. Still, this is the
ﬁrst study in its kind to analytically compare such Golgi gly-
cosylation defects between the mutant COG subunits.
Mass spectroscopical analysis of total serum N-glycans
revealed an overall decrease in sialylation and galactosylation
in all patients. Strong differences in the relative amounts of
oligosaccharides and the presence of unexpected oligosacchar-
ide structures were observed according to the affected COG
subunits. Most striking was the presence of a Man5GlcNAc2
structure in COG1 and COG7 patients, suggesting an abnor-
mal localization and/or activity of GlcNAcT1. In previous
studies also a destabilization of ManII and b-1,4-GalT1 was
noticed in the COG1 patient, likely explaining the observed
demannosylation and galactosylation defects. On the other
hand, the COG8 patient only showed a destabilization of
b-1,4-GalT1 resulting in a decreased galactosylation (12,15).
We can, however, not exclude that all observed glycosylation
defects are caused by mislocalization of the classical glycosy-
lation enzymes. Indeed, proper glycosylation is also crucially
dependent on nucleotide-sugar transporters and mislocaliza-
tion or degradation of such transporters would affect Golgi
glycosylation.
There is a strong correlation between the severities of the
trafﬁcking and glycosylation abnormalities in all patients’
cell lines. Hence it is likely that the deﬁciency in tethering
of intra-Golgi retrograde vesicles impairs recycling of the
responsible enzymes and/or nucleotide-sugar transporters
back to their correct cisternae. Given the defects in COG func-
tion and their, mostly dramatic, effects on intra-Golgi transport
and Golgi integrity, one wonders how such cells still manage
to generate a vast percentage of normal oligosaccharide
chains. After all, even the clinically and cellularly most
severe COG7 mutation succeeds partially in this task
(Fig. 3A and B). On the other hand, clinically less severe
cases such as the COG1 patient have more pronounced glyco-
sylation defects compared with others. All this suggests a high
degree of plasticity of the Golgi apparatus to maintain minimal
function even when structurally affected. Given the heavily
disorganized or even residual appearance of Golgi complexes
inthedifferentCOGmutantsandmostlythelackofrecognizable
Figure 7. Hypothetical models on (the regulation of) the action of the COG complex. Retrograde transport organelles as well as target antecedent cisternal mem-
branes are proposed to recruit single lobe A or B subcomplexes (red and blue circles) from cytosolic pools. Tethering of the vesicle to the cisternal membrane
occurs by binding of both lobes and full complex formation (A) or by directly binding of the full complex to either of the membranes (B). Recruitment of the
COG complex to the membrane may include, as yet unknown, proteins (orange and purple boxes). Also, model B suggests the presence of a long-distance tether
(green line) that initially captures the vesicle prior to COG complex recruitment. After tethering, the soluble NSF attachment protein receptor (SNARE) fusion
machinery drives the fusion of vesicle and membrane followed by dissociation of the COG complex from the membrane and from each other.
Human Molecular Genetics, 2009, Vol. 18, No. 17 3253cisternal organization, this plasticity is difﬁcult to explain only
on the basis of the ‘cisternal maturation’ model. Keeping a
minimal ﬁdelity in glycosylation could, however, be explained
by the Golgi apparatus being a two-phase membrane system
(10). In this model, enzymes and transmembrane cargo not
only rapidly partition between two lipid phases but also
exchange fast among cisternae. This rapid cargo mixing
upon Golgi entry and the absence of a deﬁned transit time
as predicted by this model increases the likelihood of cargo
to encounter the set of enzymes required for complex glycosy-
lation. One could imagine that even in severely disorganized
Golgi complexes such a system could support minimal glyco-
sylation processes as observed in the different COG patients.
Although speculative for the moment, cells harbouring
mutant COG subunits have the potency to provide the litmus
test for this provocative model on intra-Golgi transport.
Concluding remarks
In conclusion, we experimentally demonstrated here that
‘natural COG mutants’, found in CDG-II patients, allow for
a better understanding of the role of the full COG complex
and of the individual subunits and subcomplexes in tethering
Golgi vesicles. Moreover, we also highlighted the important
contribution of characterizing clinical mutations in the mol-
ecular and cell biological understanding of Golgi dynamics
and its associated functions permitting to propose novel mech-
anisms or testing existing models. The predominance of COG
mutations as a possible cause of CDG-II also predicts that
within the growing pool of unresolved cases, likely more can-
didate genes will be found whose products function in intra-
Golgi transport regulation.
MATERIAL AND METHODS
Cell culture and transfections
Primary ﬁbroblasts, obtained from patients and controls, and
HeLa cells were cultured in DMEM/F12 (Life Technologies,
Paisley, UK), supplemented with 10% Bovine Growth Serum
(HyClone, Logan, UT, USA)and were kept at 378Ci n5 %C O 2.
Antibodies
Antibodies against the COG1-8 subunits were afﬁnity puriﬁed
or crude serum rabbit polyclonal antibodies. Dilutions ranged
from 1 in 500 to 1 in 2000 for western blot and from 1 in 50
to 1 in 200 for confocal laser scanning microscopy imaging.
Anti-COG3 pab, anti-mannosidase II pab and anti-b-1,4-GalT1
mab were gifts from, respectively, V. Lupashin (University of
Arkansas for Medical Sciences, Little Rock, AR, USA),
K. Moremen (University of Georgia, Athens) and E. Berger
(University of Zu ¨rich, Zu ¨rich). Anti-GM130 mab was pur-
chased from BD Biosciences (Franklin Lakes, NJ, USA).
Plasmids
COG4 cDNA (NM_015386) was cloned into the pMSCV ret-
roviral vector (Clontech Laboratories, Mountain View, CA
94043, USA), engineered with a polylinker site, as described
before (47). For the production of retrovirus, we used the
packaging pVPACK-Ampho vector (Stratagene, La Jolla,
CA 92037, USA).
Mass spectrometric analysis of N-linked glycans released
from total plasma proteins
Analysis of N-linked glycans on plasma glycoproteins was
carried out by surface-enhanced laser desorption ionization
time-of-ﬂight mass spectrometry (Ciphergen, Fremont, CA,
USA) essentially as described by Mills et al. (48). for MALDI-
TOF mass spectrometry. Analysis of acidic N-linked glycans
was performed in negative linear ion mode. The total
N-linked glycans from plasma proteins were released enzy-
matically as described by Mills et al. (48). The reference
samples were anonymous plasma samples from patients
without CDG or a lysosomal storage disease.
Preparation of cytosol and membrane fractions
Cells of control and patient were cultured in 75 cm dishes up
to 90% conﬂuency and harvested, on ice, in 1 ml of 20 mM
HEPES–KOH buffer pH 7.4, supplemented with a protease
inhibitor cocktail. Cells were subsequently homogenized
using a ball-bearing type homogenizer. Separation of mem-
brane and cytosol was obtained upon ultracentrifugation
during 1 h at 100 000g at 48C. After removal and storage of
the cytosolic fractions, the pellet was dissolved in 1 ml
20 mM HEPES–KOH buffer pH 7.4 supplemented with
0.1 M NaCl and 1% CHAPS. After 1 h incubation at 48C the
insoluble material was pelleted upon ultracentrifugation at
55 000g during 15 min at 48C. The membrane-containing
supernatant fractions were removed and stored. The obtained
samples were concentrated by CHCl3/MeOH/H2O (3/2/1) pre-
cipitation and subsequently loaded onto a 4–12% Bis-Tris
SDS–PAGE pre-casted electrophoresis gel (Invitrogen, Carls-
bad, CA, USA) and further processed as described in the
Supplementary Material.
Glycerol gradient centrifugation
Preparation of the cytosolic and membrane fractions was iden-
tical to the protocol above. After collection, the samples were
loaded onto a 12 ml 10–30% glycerol (w/v) gradient. The gra-
dients were centrifugated in a Beckman SW40 rotor at
120 000g during 15 h, with slow acceleration and deceleration.
Fractions of 1 ml were collected via a hole punched in the
bottom of the tubes. Concentration of the samples was also
done by a CHCl3/MeOH/H2O (3/2/1) precipitation, followed
by loading of the resulting fractions onto a 4–12% Bis-Tris
SDS–PAGE pre-casted electrophoresis gel and further pro-
cessed as described in the Supplementary Material.
ER–Golgi trafﬁcking assay
Cells were seeded onto glass coverslips in a six-well plate and
allowed to grow until 75–90% conﬂuency during 48 h. To
assay the retrograde Golgi-to-ER trafﬁcking BFA, purchased
from Sigma (St Louis, MO, USA), was diluted up to 5 mg/ml
in normal growth medium and this solution was pre-warmed at
3254 Human Molecular Genetics, 2009, Vol. 18, No. 17378C, before adding to the cells. Two millilitre of medium con-
tainingthedrugwasaddedperwellandthecellswerereplacedin
the incubator as soon as possible. Immediately after the end of
the treatment, the plates were put on ice, the medium was
taken off and 1 ml of 4% paraformaldehyde was added per
well. After a 30 min ﬁxation the coverslips were further
stained for GM130 and mannosidase II, as described in the
Supplementary Material.
To assay the anterograde ER-to-Golgi trafﬁcking and the
reformation of the Golgi from the ER, BFA was diluted up
to 0.25 mg/ml in normal growth medium. After pre-warming
the solution to 378C, 2 ml was added per well and the cells
were replaced in the incubator for 1 h. Afterwards, the cover-
slips were extensively washed in PBS and placed in new wells,
containing fresh, BFA-free, medium. The plates were again
placed in the incubator, for 90 min, after which the cells
were put on ice, washed and ﬁxed with paraformaldehyde.
Again this treatment was followed by immunoﬂuorescence
staining for GM130 and mannosidase II, as described in the
Supplementary Material.
Transmission electron microscopy
For TEM cells were grown in a 25 cm
2 ﬂask and, upon reach-
ing 95% conﬂuency, ﬁxed for 30 min at RT with 2% parafor-
maldehyde in 0.1 M phosphate buffer pH 7.4. After removal of
the ﬁxative cells were kept in 4% paraformaldehyde until pro-
cessing for EPON embedding, as described previously (49)
and analyzed after ultrathin sectioning.
Production of retroviral particles
Cultured 293T cells are splitted 1 over 20 before reaching 70%
conﬂuency and plated in a 15 cm dish. Upon reaching 90% of
conﬂuency the cells are transfected with the pMSCV vector
and the pVPACK-Ampho plasmid (in total 20 mg) in serum-
free DMEM/F12 medium (Life Technologies, Paisley, UK)
and using Fugene-6 (Roche Applied Science, Indianapolis,
IN, USA). The medium is replaced 24 h after transfection
and 24 h later the ﬁrst retroviral-containing supernatant is har-
vested, using a blunt-end needle and a 0.45 mm ﬁlter. In total,
four harvests were obtained, with an alternating time differ-
ence of 6 and 12 h between two harvests. Obtained samples
were instantly frozen in liquid nitrogen and stored at 2808C.
Transduction of ﬁbroblasts
One day in advance cells are splitted into a six-well plate at
150 000 cells per well, in order to have a 50–70% conﬂuency
the day after. The medium is removed and 1 ml medium con-
taining 16 mg polybrene (Sigma) and 1 ml of viral supernatant
are added. After 24 h, the selection using puromycin (Sigma)
is started in order to obtain a stable cell line.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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